Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.97M | 15.47M | 12.44M | 10.12M | 10.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.82M | 28.56M | 26.29M | 23.50M | 25.16M |
| Operating Income | -32.82M | -28.56M | -26.29M | -23.50M | -25.16M |
| Income Before Tax | -32.96M | -28.43M | -26.05M | -22.40M | -23.24M |
| Income Tax Expenses | 79.20K | 79.20K | -101.00K | 90.80K | 98.80K |
| Earnings from Continuing Operations | -33.04 | -28.51 | -25.95 | -22.49 | -23.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.04M | -28.51M | -25.95M | -22.49M | -23.34M |
| EBIT | -32.82M | -28.56M | -26.29M | -23.50M | -25.16M |
| EBITDA | -32.75M | -28.49M | -26.21M | -23.41M | -25.07M |
| EPS Basic | -0.32 | -0.29 | -0.29 | -0.28 | -0.30 |
| Normalized Basic EPS | -0.20 | -0.18 | -0.18 | -0.17 | -0.19 |
| EPS Diluted | -0.32 | -0.30 | -0.29 | -0.28 | -0.30 |
| Normalized Diluted EPS | -0.20 | -0.18 | -0.18 | -0.17 | -0.19 |
| Average Basic Shares Outstanding | 410.91M | 383.25M | 354.52M | 330.22M | 315.31M |
| Average Diluted Shares Outstanding | 410.91M | 383.25M | 354.52M | 330.22M | 315.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |